
-
Prelude Therapeutics Incorporated NasdaqGS:PRLD Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Location: 175 Innovation Boulevard, Wilmington, DE, 19805, United States | Website: https://preludetx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-30.23M
Cash
99.07M
Avg Qtr Burn
-26.33M
Short % of Float
4.84%
Insider Ownership
11.37%
Institutional Own.
69.69%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Phase 2 Initiation | ||
PRT543 (PRMT5 inhibitor) Details Myelofibrosis, Solid tumor/s, Myelodysplastic syndrome, Cancer | Phase 1 Data readout | |
PRT3645 (CDK4/6 inhibitor) Details Head and neck cancer, Glioblastoma, Non-small cell lung carcinoma, Breast cancer | Phase 1 Data readout | |
PRT3789 [SMARCA2 degrader] Details Non-small cell lung carcinoma, gastric and esophageal cancer | Phase 1 Data readout | |
PRT7732 [SMARCA2 degrader] Details SMARCA4-mutated cancers | Phase 1 Data readout | |
PRT2527 (CDK9 inhibitor) Details Acute myeloid leukemia, Hematologic malignancies | Phase 1 Update | |
PRT1419 (MCL1 inhibitor) Details Hematologic malignancies, B-cell malignancies, Relapsed/refractory acute myeloid leukemia, Solid tumor/s | Failed Discontinued | |
PRT811 (PRMT5 inhibitor) Details primary central nervous system lymphomas, Cancer, Glioblastoma | Failed Discontinued |